CCL

Összesen 1 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM072318
Első szerző:Kocsis Judit (onkológus)
Cím:First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer : efficacy and Safety Analysis / Judit Kocsis, Éva Szekanecz, Ali Bassam, Andrea Uhlyarik, Zsuzsanna Pápai, Gábor Rubovszky, Emese Mezősi, Károly Rucz, Ildikó Garai, Endre Nagy, Iván Uray, Zsolt Horváth
Dátum:2019
Megjegyzések:Background Medullary thyroid cancer (MTC) is a rare disease,the prognosis of advanced and metastatic disease is poor andfew therapeutic options are available in this setting. Based onthe results of phase II and III studies with sorafenib in differentiatedthyroid cancer and the lack of availability of registeredtyrosine kinase inhibitors, vandetabin and cabozantinib in Hungary,we designed a uncontrolled, prospective efficacy andsafety study of patients with metastatic MTC treated with firstlinesorafenib in five Hungarian oncology centers.Methods Ten consecutive patients with progressive or symptomaticmetastatic MTC were included and started sorafenib400 mg twice a day between June 2012 and March 2016. Theprimary end point was median progression-free survival(mPFS). Secondary endpoints included disease control rate,biochemical response, symptomatic response and toxicity.Results Four patients achieved partial remission (40 %) accordingto RECIST 1.1 evaluation. Five patients had stable diseasebeyond 12 months (50 %) and one patient had progressivedisease (10 %). Median PFS was 19.1 months. The disease controlrate was 90 %. Association between radiologic responseand biochemical or symptomatic response was inconsistent.Most common side effects were Grade 1-2 fatigue (60 %),palmar-plantar erythrodysesthesia, rash/dermatitis 50-50 %,alopecia 40 %.Conclusions In our prospective case series in patients withMTC first-line sorafenib showed at least similar efficacy as inother small phase II trials and case reports. Based on comparableefficacy with registered tyrosine kinase inhibitors and it'smanageable toxicity profile, we believe that sorafenib has rolein the sequential treatment of MTC.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Experimental and clinical endocrinology & diabetes. - 127 : 4 (2019), p. 240-246. -
További szerzők:Szekanecz Éva (1968-) (onkológus szakorvos) Bassam, Ali Uhlyarik Andrea Pápai Zsuzsanna Rubovszky Gábor Mezősi Emese Rucz Károly Garai Ildikó (1966-) (radiológus) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Uray Iván Péter (1970-) (kutatóorvos) Horváth Zsolt (1964-) (onkológus, belgyógyász, klinikai farmakológus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1